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quantitative data, with the end goal of generating imaging biomarkers as 
decision support tools for clinical practice. The use of imaging data from 
routine clinical work-up has tremendous potential in improving cancer care 
by heightening understanding of tumor biology and aiding in the 
implementation of precision medicine. As a noninvasive method of 
assessing the tumor and its microenvironment in their entirety, radiomics 
allows the evaluation and monitoring of tumor characteristics such as 
temporal and spatial heterogeneity. One can observe a rapid increase in 
the number of computational medical imaging publications - milestones 
that have highlighted the utility of imaging biomarkers in oncology. 
Nevertheless, the use of radiomics as clinical biomarkers still necessitates 
amelioration and standardization in order to achieve routine clinical 
adoption. This Review addresses the critical issues to ensure the proper 
development of radiomics as a biomarker and facilitate its implementation 
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Medical image processing and analysis (also known as Radiomics) is a rapidly growing discipline that maps 
digital medical images into quantitative data, with the end goal of generating imaging biomarkers as decision 
support tools for clinical practice. The use of imaging data from routine clinical work-up has tremendous 
potential in improving cancer care by heightening understanding of tumor biology and aiding in the 
implementation of precision medicine. As a noninvasive method of assessing the tumor and its 
microenvironment in their entirety, radiomics allows the evaluation and monitoring of tumor characteristics such 
as temporal and spatial heterogeneity. One can observe a rapid increase in the number of computational 
medical imaging publications - milestones that have highlighted the utility of imaging biomarkers in oncology. 
Nevertheless, the use of radiomics as clinical biomarkers still necessitates amelioration and standardization in 
order to achieve routine clinical adoption. This Review addresses the critical issues to ensure the proper 
development of radiomics as a biomarker and facilitate its implementation in clinical practice. 
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Key message: 
In oncology, quantitative analysis of high throughput imaging data, radiomics, has immense potential to 
deepen knowledge on tumor biology and improve clinical decision-making. Recently, radiomics has notably 
progressed, benefiting from increased available data, advances in machine learning and possibility to integrate 
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Introduction  
Medical images possess valuable information which can be harnessed through computer assisted 
interpretation. This technique, termed radiomics, is a rapidly-emerging discipline with the goal of extracting 
quantitative data from medical images to be used as clinical decision support tools[1–3]. In the context of 
oncology, information obtained from standard imaging modalities (Computed Tomography Scan (CT), 
Magnetic Resonance Imaging (MRI) and Positron Emission Tomography Scan (PET)), usually refers to simple 
traits such as gross shape, contrast enhancement, and size. However, imaging information is much richer, and 
the goal of radiomics is to extract high throughput quantitative features, covering the fields of texture, advanced 
shape modeling, and heterogeneity, to name a few. The increasing resolution quality has led to 3-
dimensional(3D) image acquisitions containing millions of voxels available for analysis, making the 
development of radiomics a natural progression, as more data necessitated increased computing capabilities 
to harness more information. 
 
Radiomics has immense potential to improve knowledge in tumor biology and guide the management of 
patients at bedside[4]. Medical image analysis allows tumor monitoring across time, being routinely acquired 
throughout the course of treatment. Thus, imaging biomarkers may be used for and contribute to cancer 
detection, diagnosis, choice of therapeutic strategy, prognosis inference, prediction of response, and 
surveillance. Tumors exhibit spatial heterogeneity and temporal variation, recognized as a major cause of 
treatment failure and modulators of intrinsic tumor aggressiveness[5–7]. Imaging allows assessment of the 
entire tumor plus surrounding tissue - it is not blind to global heterogeneity - as opposed to invasive needle 
biopsies that are limited by sampling site. Radiomics could serve as a ‘virtual biopsy’ that would provide 
complementary information to, but not replace, conventional biopsies which remain vital in deep genomic 
analysis. 
 
This Review will systematically go through the radiomics pipeline, the significant milestones achieved in 
oncology, and future perspectives for improvement. The aim is to increase the awareness and interest of the 
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oncology community to radiomics, demystify the field for non-imaging experts, and engage the community to 
be involved in its further development and adoption in clinical practice. We will demonstrate the potential of 
radiomics to advance precision medicine. 
 































































Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology 
 
Radiomics Pipeline 
The process of radiomics consists of discrete steps: image acquisition and segmentation, feature extraction, 
statistical learning and 3D rendering (Figure 1).  
Image acquisition and segmentation 
Radiomics may be applied to different/multiple modalities, and selecting the one(s) to investigate depends on 
several factors. Radiomics quantitatively explores the distribution of signal intensities within a region or volume 
of interest (ROI/VOI). The spatial resolution of images varies, being around 1mm for CT and MRI and 4mm for 
PET. ROIs that are too small (e.g. sub-centimeter nodules) may not provide sufficient voxel information for 
analysis, whereas ROIs that are too large may be impacted by tumor heterogeneity (e.g. large tumors often 
present hypoxia in their centers). Standardization and calibration of non-ionizing procedures (Ultrasound, MRI) 
are intrinsically more complex than techniques based on photon detection (PET or CT)[8]. The minimal 
concentration of a molecule that is detectable on PET is 10-12 moles compared to 10-3 moles for MRI, meaning 
that the former might be 109 more sensitive for in vivo molecular imaging. Patient motion and respiration during 
acquisition affects the quality of reconstructed images; a CT is usually acquired in a few seconds whereas 
functional (MRI) or molecular (PET) imaging lasts several minutes. Data might be extracted from retrospective 
standard-of-care images, leading to large pool of patients. However, acquisition parameters vary considerably, 
which can introduce signal variations not due to biologic effects[8–10]. As with other high throughput 
technologies such as genomics, the aggregation of multiple datas ts in radiomics can lead to substantial 
unwanted effects on the data. In determining the inclusion criteria for studies, an option is to have a large 
cohort in order to be less sensitive to variations due to acquisition/reconstruction parameters, or have a small 
cohort with homogenous data.  
Crucial in the process is correct delineation of ROIs to be analyzed. Segmentations must be reproducible and 
reliable. Automatic methods are preferable for precision and efficiency. It has been proven that inter- and intra-
observer variabilities are lower in automatic vs. semi-automatic vs. manual delineation[10–13]. However, semi-
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automatic delineation is usually mandatory, since automated methods are feasible only if there are strong 
signal differences between the lesion and the background. This is observed in PET and CT of pulmonary 
tumors, and possibly in certain MRI sequences. Commonly, such as in tumors surrounded by relatively 
homogenous normal structures, an experienced physician is required to correct contours, entailing computer-
aided outline detection followed by manual correction. 
 
Currently, there are several open source platforms equipped with automatic and semi-automatic contouring 
functions, such as 3DSlicer (Growcut algorithm)[14], which have active online support, and are continuously 
updated. Generated contours should be stored in an easily utilizable format for analysis across various 
platforms. Commonly used is DICOM-RTSTRUCT, which enables data sharing within and outside of the 
radiotherapy workflow, containing information on the images and ROIs[15]. Other formats such as Analyze[16] 
and NIfTI are also used[17]. 
 
Feature extraction  
Preprocessing 
Raw imaging data need pre-processing to discriminate the signal from the noise. One optional step is filtering 
the signal within the ROI, which defines the frequencies to be utilized for subsequent analysis[18]. The choice 
of filter is guided by the nature of the imaging modality and tumor tissue. Another is the discretization or 
resampling[19,20] of signal intensities that partitions continuous voxel values to finite/nominal intervals called 
bins. Techniques involve either absolute (using a fixed bin size) or relative (using a fixed number of bins whose 
size depends on the minimum and maximum values within the tumor) discretization. The choice of method is 
crucial as extracted features vary accordingly[21,22]. Several studies[19,20,23] have shown that absolute 
discretization results to features with better repeatability and lower sensitivity to changes, with the added 
advantage of not being volume dependent. 
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Radiomics Features  
Features may be classified into several categories. There are quantitatively-extracted descriptors of size, 
shape, and other radiologic terminologies which characterize the tumor surface. First-order statistics are used 
to study the distribution of voxel values without considering spatial relationships[24]; second order statistics 
characterize spatial relationships between voxels, initially described by Haralick[25] such as the co-occurrence 
matrix (GLCM), gray-level run length matrix (GLRLM)[26], gray-level size zone matrix (GLZLM)[27], and the 
neighborhood gray-level different matrix (NGLDM)[28]. Filter grids such as Gabor and Fourier may be used 
both in the pre-processing step and for extracting spatial or spatio-temporal features[29,30]. A limitation is 
some extracted values are dependent on the ROIs contoured.  
  
The extracted features can be global (one value for the whole ROI), or local (a value per image patch) when 
inhomogeneous patterns are present in the image, where dimensionality significantly increases if simple 
concatenation of local descriptors is performed. For this, more advanced frameworks explore compact 
statistical representations based on coding structures/dictionaries. When visual vocabularies and visual word 
weights are learned jointly, performance can be improved, as shown in classification of breast tissue density in 
mammograms, lung tissue in high-resolution CT, and brain tissue in MRI[31]. A more detailed review on 
texture analysis methods focusing on microscopy images of cells or tissues can be found in[32]. 
The stability and the accuracy of features should be confirmed through the use of test-retest datasets; a good 
practice policy is to eliminate features that prove to be unreliable in the test-retest. To this end, several 
datasets are publicly available. Of note is the RIDER[33] dataset, which allows validation of results in the same 
set of patients with two scans taken 15 minutes apart. 
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Statistical Learning 
The impact of the high number of radiomics variables 
The current radiomics pipeline typically incorporates around 50-5000 quantitative features (p), and these are 
still expected to increase. Meanwhile, the number of patients (n) in studies remains small, leading to a situation 
where p>>n, or the "curse-of-dimensionality"[34]; resulting in a high probability of false positive results[35]. 
Adjustments for multiple comparisons (Bonferroni correction[36]) and controlling the false discovery rate 
(Benjamini-Hochberg[37]) are commonly utilized methods to address this. Another issue is overfitting, which 
can reduced by cross-validation with independent training and validation datasets[34]. Several techniques of 
dimensionality reduction can be used to reduce the number of variables for analysis by exploiting statistical 
correlations and data redundancy[38]. Unsupervised techniques map the data through a linear (e.g. Prinicipal 
and Independent Component Analyses) or non-linear (e.g. ISOMAP, Locally Linear Embedding) transformation 
in a lower-dimensional space, such that information loss is minimized, whereas supervised techniques select a 
subset of the original variables such that prediction accuracy is maximized. Feature selection can be 
performed independently, before classification or regression, or be combined into a single mathematical 
problem (e.g. Lasso, ElasticNet)[39]. Attention has to be given in the case of supervised learning and small 
datasets to overfit the data; feature selection should be performed externally to the cross-validation procedure 
to correctly estimate the empirical error.  
  
Promising machine learning approaches for prediction and classification tasks 
Machine learning approaches[40] such as decision trees and random forests[41–46], support vector 
machines[39,47,48] and more recently deep neural networks[49] appear to be promising in the domain of 
medical image computing. The recent increase of available annotated imaging data in public portals expedited 
the use of these techniques. In particular, deep convolutional neural networks (CNNs) have been shown to 
excel at learning a hierarchy of increasingly complex features directly from raw data, alleviating the explicit 
extraction of low-order, pre-defined features. In such frameworks, feature extraction and selection are 
performed jointly with classification within the optimization of the same deep architecture, thus performance 
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can be tuned in a systematic fashion. Common CNN schemes train patch-level classifiers[50] that 
automatically locate discriminative regions and then aggregate local predictions. The learning process is 
usually facilitated by pre-training using standardized data followed by supervised training for fine-tuning.  
 
Thus far, CNNs have been shown to excel in the detection and classification of pulmonary nodules in large 
series of lung CTs from the Lung Image Database Consortium (LIDC-IDRI)[41,43,51]. A comparison in 
mortality prediction from chest CTs[52] between (i)a unified deep learning framework (features and classifier 
are automatically learned in a single optimization process) and (ii)a standard multi-stage framework (pre-
defined radiomics features are introduced into a classifier), showed increased accuracy of the deep learning 




The visualization of the entire tumor, commonly performed in diagnostic radiology, is possible through 3D 
rendering[55]. Radiomics takes this a step further through visualization and assessment of tumor heterogeneity 
which provides invaluable information in clinical oncology and in cancer research. For instance, this can direct 
which intra-tumoral region is best to biopsy for adequate samples. In radiotherapy dose painting, rendering is 
instrumental in visualizing treatment-resistant regions, facilitating dose escalation and consequently decreasing 
normal tissue toxicity[56]. Theragnostic imaging[57], the use of molecular/functional imaging to prescribe 
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Significant milestones of radiomics in oncology 
Radiomics is substantial in oncology, not surprising given the increased availability of and information in patient 
imaging data. Oncologic imaging is a substantial part of a radiologists' daily workload. More than 128 million 
imaging examinations were realized in the United States in 2015, greater than 60% of which were CTs (Figure 
2B); and an increase of >36% in use of advanced imaging was seen from 2005 to 2015[59], reiterating the vast 
amount of available data. This section aims to depict the impact of radiomics in each stage of cancer care, with 
tables outlining key details. 
 
Advancements in the understanding of tumor biology  
Tumor heterogeneity 
The extensive genetic and molecular landscape within tumors -tumor heterogeneity- is known to be specific to 
the malignant process. Intra-tumoral heterogeneity is dynamic and is modified by therapeutic effects. 
Heterogeneity may portend treatment resistance and poor outcomes due to the emergence of resistant 
subclonal populations[60]. Through quantitative serial analysis of imaging, both temporal and spatial 
heterogeneities may be analyzed. In particular, texture analysis is emerging as an effective method to quantify 
heterogeneity. Table 1 displays some representative work. To illustrate, in CTs of lung adenocarcinomas, 
entropies of the tumor core and boundary regions were computed separately, with results showing that a 
higher ratio between the two are associated with poorer outcome[61]. Thus, this imaging phenotype may 
reflect distinct traits such as necrosis in the core and proliferation in the periphery. In PET, texture analysis 
showed that healthy lung tissues are more homogenous than malignancies, and texture features differentiated 
tumor histologies[20]. Similar studies on texture heterogeneity, with or without other feature classes, depict 
quantitative imaging traits mirroring genomic and molecular phenotypes [62–69].  
 
Modeling of key oncogenic processes  
Several biological processes are known to be necessary components of oncogenesis[70,71]. Various 
molecular biology techniques have been developed to better appraise biological and genetic causes of these, 
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and the emergence of quantitative imaging analysis is a promising tool to complement and enhance existing 
techniques.  
 
A study in lung cancer used an angiogenesis-related marker injected in specimens, and linear correlations 
were shown between CT texture heterogeneity features and percentage of the tumor stained for the 
marker[72]. In glioblastomas, the ‘contrast enhancement imaging phenotype’ was significantly associated with 
tumor angiogenesis[64]. In breast cancers, certain computer extracted imaging phenotypes of MRIs have been 
shown to differentiate subtypes[62]. 
 
In lung cancers, multi-categorical quantitative imaging features were shown to reflect tumor hypoxia[63,66]. In 
the preclinical setting, causal relationship between genetic changes and imaging features was demonstrated 
by pre-imaging administration of doxycycline which induces hypoxic changes[73]. Clinically, these results may 
be helpful in identifying tumor resistance and the need for intensified regimens. 
 
Further, radiomics phenotypes have been shown to correlate with mRNA and protein expression in breast 
MRIs[74], alluding to the underlying mechanisms of tumor invasion. In glioblastomas, peritumoral fluid 
attenuation inversion recovery MRI signal abnormalities were found to reflect genes and microRNAs 
accounting for cellular migration and invasion[75]. In addition, lymphocyte infiltration has been reflected in 
imaging features of HER2+ breast cancers[76].  
 
Radiomics features also appear to model tumor proliferation. A landmark study in liver cancer demonstrated 
that the combination of 28 traits could reconstruct as much as 78% of transcriptome variation, and were 
specifically associated with genes involving cell proliferation[77]. In breast cancers, analysis of TCGA-TCIA 
data revealed clear associations between radiomics phenotypes and proliferation at the protein and gene 
expression levels. Imaging phenotypes of increased tumor size were also associated with P-cadherin 
expression, shown to correlate with increased proliferation[74]. 
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Better implementation of precision medicine 
Precision medicine is an approach for disease treatment and prevention that takes into account individual 
variability in genes, environment, and lifestyle; integrating information from multiple sources with the end goal 
of personalized management[78]. In this section, some key radiomics applications are described.  
 
Diagnosis 
One of the biggest challenges in oncology is the development of accurate, cost-effective screening procedures. 
In the National Lung Cancer Screening Trial (NLST), low-dose CTs interpreted by radiologists have been 
shown to be beneficial in mortality reduction in a cohort of 53,000 patients[79]. These however exhibit high 
false-positive rates (>90%); wherein radiomics could be effective in improving specificity. Using NLST data, 
patients with screening-detected lung cancer were matched with subjects with benign nodules. Accuracies of 
80% and 79% were found for predicting nodules that will become cancerous at one and two years, 
respectively[42]. Using LIDC-IDRI patients with a total of 42,340 lesions (through data augmentation), deep 
convolutional sequencers detected malignant nodules with diagnostic accuracy, sensitivity and specificity 
>75%[41]. Two studies[43,80] with 914 and 1375 lesions, respectively, published promising results with 
predictive performances ranging from 60 to 80%. Notably, multi-scale CNNs attained 86.84% accuracy on 
classification with automatic nodule detection and segmentation[43]. Other publications in lung carcinomas 
reveal similar findings[46,81,82]. Table 2 presents representative publications concerning diagnosis.  
 
Staging and prognosis 
Accurate staging determines the aggressiveness of therapeutic strategy and spells the difference between 
curative and palliative treatments, requiring constant advancements in imaging techniques to improve decision-
making. In colorectal carcinomas, for which liver metastases are frequent, radiomics features extracted from 
unenhanced hepatic CT scans showed texture abnormalities suggestive of metastases in apparently disease-
free areas[83]. This could streamline the staging process and minimize treatment delays with the information 
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steering the clinician towards doing confirmatory examinations for patients at risk. Plus, early detection of 
metastases may increase chances of complete tumor eradication.  
In prognostication, increased shape complexity in lung adenocarcinoma[61] was associated with poorer clinical 
outcomes. Morphologically similar tumors by visual inspection turned out to have large differences in 
quantitative parameters, denoting that radiomics can supplement radiologists’ interpretations. Another 
study[84] demonstrated that radiomics features are prognostic for both distant metastasis and survival, and a 
radiomics signature significantly improves prognostication when added to clinical data. Similar studies were 
published in colorectal cancers[85,86]. In a large cohort involving multiple datasets with varying tumor types[4], 
differences in imaging phenotypes showed clinical significance and impact on prognosis. These results were 
reiterated in a dataset of almost 900 patients[87] and externally validated in oropharyngeal cancers[88]. Table 
3 shows recent radiomics publications on tumor staging and prognosis.  
 
Prediction of treatment response  
Radiomics features could be used to predict which patients would respond to a treatment regimen. Table 4 
summarizes notable publications. In glioblastomas, a robust association between radio-phenotypes and gene 
expression has been shown, including a link with epidermal growth factor receptor (EGFR) 
overexpression[64,89]. Radiomics features have been shown to stratify treatment outcomes from angiogenic 
therapy in recurrent glioblastomas[90]. EGFR mutation[91] and response to Gefinitib[92] were also reflected in 
a combination of features in lung cancers. With the rapid rise in targeted therapy, it is worthwhile to continue 
discovering radiogenomic associations that may influence management. An imaging surrogate to could aid 
patient selection and avoid unwarranted expense and toxicities for non-responders. 
 
In the neoadjuvant chemotherapy setting, a multiparametric model in breast MRIs identified non- responders 
with 84% sensitivity[93], with the goal of developing a computer-assisted prediction solution, which may be 
more cost-effective than molecular assessments. In rectal carcinomas, a combination of radiomics features 
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was seen to be predictive of pathologic response to neoadjuvant treatment[49]. Studies in other cancer 
localizations[94–97] have shown the possibility of assessing treatment response using imaging markers.  
 
In the advent of immunotherapy, there have been been patients who experience pseudoprogression 
(PSPD)[98],which has been shown to be due to lymphocyte infiltration in and around the tumor[99]. A study 
demonstrated that a radiomics signature from CTs could reflect tumors with increased lymphocytes and 
discriminate PSPD from true progression[100], possibly aiding decision-making for equivocal cases.  
 
Disease monitoring and surveillance 
Inflammation leads to post-treatment reactions that might complicate response evaluation by imaging. In this 
context, functional imaging helps differentiate scar tissue from viable tumor, but equivocal cases remain. 
Radiomics can further enhance evaluation. For instance, texture features from CT images of lung cancer 
treated with stereotactic ablative body radiotherapy (SABR) showed that the ground glass appearance (an area 
of hazy increased lung opacity through which vessels and bronchial structures may still be seen[101]), following 
SABR predicts recurrence versus radiation-induced lung injury, which has a similar radiologic picture[102]. This 
is particularly useful because lung cancer typically progresses quickly; hence the decision for salvage therapy 
is most valuable if made early, likely providing more treatment options compared to late-detected disease. In 
addition, a pilot study on renal cell cancers has demonstrated the possibility of capturing sub-visual treatment-
related imaging changes[103].  
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Perspectives  related to the effective translation of the radiomics biomarkers into the clinic  
There is convincing evidence that radiomics could be an invaluable tool in revolutionizing oncology. Significant 
progress has been made, but further improvements are imperative to achieve routine utilization from bench to 
bedside.  
 
Standardization and the perspective relative to molecular biomarkers 
Radiomics literature is constantly growing, and we predict that it will follow the curve of the molecular 
biomarkers as interests and funding increase (Figure 2A). At present, however, the existing level of evidence is 
insufficient (Figure 3). There are notable differences in terms of sample size, methodology, performance 
metrics, and clinical utility; reiterating that improvements are essential. 
 
As investigators have learned from discovery of biomarkers[104,105], there are pitfalls to be avoided. In the 
same way as the REporting recommendations for tumour MARKer prognostic studies (REMARK)[106] or the 
Minimum information about a microarray experiment (MIAME)[107] guidelines, recommendations specific to 
radiomics are necessary. In reporting, key elements should be sufficiently detailed and made available to allow 
comparisons and validation: (i)raw imaging data including acquisition parameters, (ii)ROIs, (iii)radiomics 
features and the extraction software, methods, formulae used and (iv)statistical learning methods. Meriting 
attention is the non-standardized names of extracted features, such that two publications might discuss a 
feature with the same formula/definition but call these differently.  
  
The recently published roadmap for imaging biomarkers[108] is a notable advancement, showcasing key 
recommendations for clinical translation of radiomics. Also admirable are large initiatives aiming to develop 
automatic segmentation solutions such as the Google-National Health Service partnership DeepMind Health 
project[109]. Another is the Grand Challenges in Biomedical Image Analysis[110], with goals of developing 
algorithms for specific problems such as the Lung Nodule Analysis (LUNA) Challenge[111], a large-scale 
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automatic nodule detection with 888 patients and The Digital Mammography (DREAM) Challenge[112] aiming 
to improve predictive accuracy of digital mammography with over 640,000 images. 
  
To ensure robustness and dissemination of radiomics-based predictive tools, standardization of imaging 
protocols and feature calculations is ideal, but seldom attainable[10, 113]. Imaging performed at different 
centers leads to bias[10, 114]. In fact, significant variation of radiomics features was observed across different 
CT scans through a phantom experiment[113]. The use of credentialing scanners, careful study design, noise 
reduction, and statistical analyses adjusted to account for unwanted effects are possible solutions. Table 5 
highlights the current challenges and corresponding recommendations in radiomics.  
 
Actual data access  
Improving data management is challenging for a number of reasons including (i)administrative (manpower), 
(ii)ethical (patient privacy), and (iii)personal/institutional (intellectual property). One successful undertaking is 
TCIA[115], through which investigators have access to robust anonymized imaging data in easily utilizable 
DICOM format.  
 
Researchers should be encouraged to submit data to a centralized online radiomics repository akin to the 
Gene Expression Omnibus[116] for microarrays. A standardized non-software dependent format of storing and 
annotating data will facilitate multi-platform utilization. These will not only be useful before starting research 
projects, but also during and after; ensuring the integrity and availability of information. These must allow 
incorporation of image features, annotations, medical information, and genetic data in order to create 
prognostic and predictive models correlating imaging with genetic phenotypes and clinical outcomes. It is 
critical that the fidelity of the data is maintained and access is regulated, for which competent system 
administrators are mandatory. These are big steps, but we believe they are essential for the advancement of 
the discipline. Forming a multinational consortium may be a prudent solution, some of whose functions would 
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be to (i)draft guidelines on data collection, anonymization, and sharing, (ii)to standardize reporting of radiomics 
studies.  
 
Improving multidisciplinary network and dissemination of radiomics 
Significant efforts have been made to address these issues. The National Cancer Institute, in cooperation with 
other societies like the Canadian Institute of Health Research, Cancer Research United Kingdom and 
American College of Radiology Imaging Network, have supported initiatives, including the Quantitative Imaging 
Network (QIN), to promote the development of QI methods, annotated image databases, and QI 
standards[117]. Other significant efforts include the Quantitative Imaging Biomarkers Alliance (QIBA), a critical 
component of US’ Cancer Moonshot initiative[118], and the Euregional Computer Assisted Theragnostics 
project (EuroCAT)[119], whose goals include enhancing data sharing and facilitating patient recruitment in 
clinical trials. More initiatives are necessary, with multidisciplinary working groups that include oncologists, 
radiologists, medical physicists, applied mathematicians, and computer scientists, to improve the field and 
educate people on its use such that it can become a reliable part of a decision support system in oncology. 
Radiomics has been gaining ground in terms of exposure and interest in recent scientific congresses, with the 
number of publications per year almost doubling in the last three and almost tripling in the last five years (197 
in 2015, an increase of 77% since 2013 and 186% since 2011) (Figure 2A). This is translated in increased 
exposure of radiomics in current radiology meetings (e.g. RSNA) and in major oncology meetings (e.g. ASCO, 
ESMO, AACR, ASTRO). This is a formidable start but efforts need to be increased.  
 
 



































































Imaging biomarkers constructed from quantitative image analysis have great potential to advance precision 
medicine and to enhance cancer biology knowledge. As radiomics cements its position in translational cancer 
research to attain utilization at bedside, we anticipate radiomics data being integrated and analyzed with 
genomics, proteomics and other -omics; providing information invaluable in personalized medicine. Radiomics 
will certainly progress further with the advent of more imaging data, better algorithms, and availability of other 
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Figure 1: The radiomics pipeline, showing the major steps: image acquisition and segmentation, feature 
extraction, three-dimensional (3D) rendering and statistical learning. Important to note is that radiomics 
data is meant to be integrated and analyzed with clinical, pathologic and –omics data to improve precision 
medicine.  
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Figure 2A: Comparison of publications on radiomics and molecular biomarkers. 2B: Trends in imaging 
utilization in the USA  
Figure 2A, Figure2B  
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Texture features (standard deviation 
and mean value of positive pixels) are 
associated with tumor hypoxia [Glut1/ 








T: 26 153 computational image features, 
26 semantic image features, and a 
PET SUVp 
Generalized linear 
regression with lasso 
regularization 
Image features associate with publicly 
available gene expression pathways 
(Hypoxia, KRAS pathway) with 










33 mice  625 radiomics features (intensity, 
shape, texture, wavelet features, 
Laplacian of Gaussian features) 
Intra-class correlation 
coefficiant rank, based 
on the 50% top-
ranked features 
Radiomics features demonstrate the 
causality between genomics changes 







T: 23 (1) infiltrative versus edematous T2 
abnormality, (2) degree of contrast 
enhancement, (3) necrosis, (4) 
supraventricular zone (SVZ) 
involvement, (5) mass effect, and 
(6) contrast-to-necrosis ratio. 
 
Resampling statistics, 
analyse of variance, 
Pearson correlation 
coefficient 
Gene-to-trait associations were found 
such as contrast-to-necrosis ratio with 
KLK3 and RUNX3; SVZ involvement 
with the Ras oncogene family and the 
metabolic enzyme TYMS; and 
vasogenic edema with the oncogene 










10 binary imaging traits 
(enhancement, necrosis, mass 
effect,T2 edema, cortical 
involvement, SVZ involvement, C:N 






Significant associations were found 
between: angiogenesis and tumor 
hypoxia with the contrast enhancement 
imaging phenotype (p=0.012); 
proliferation gene-expression signature 
and mass effect phenotype (p=0.0017); 
EGFRq protein overexpression and 












Quantitative models of 







Imaging traits associated with 
upregulation of mRNA involved in 
cellular migration/invasion 
(PERIOSTIN), which was seen to 










Low order texture features 
computed upon the pixel intensity 
distribution. Laplacian of Gaussian 
transformation, spatial scale filters 
Multivariate Cox 
regression model; no 
correction for multiple 
testing 
Tumor texture features are associated 
with microvessel density, VEGFt, 
soluble VEGFt receptor-1, and overall 
survival, and that the mean value of 
positive pixels is an independent 
prognostic factor in multivariate analysis 
(p=0.01) 







































































T: 112 PADUA scoring system: Exophytic, 
Longitudinal, Rim location, Renal 
sinus, UCS, Tumor size, Face 
location 
Stratified according to 
PADUA score; 
correlation of the 
PADUA system and 
its radiological 




Imaging features of PADUA scores may 
serve as molecular surrogates for RCC 
diagnosis, prognosis and personalized 
treatment for patients with specific 
genomic profiles. Higher PADUA scores 
were significantly associated with 
epithelial to mesenchymal transition 
pathways(p<0.001) 
* aCT: Computed tomography scan, bMRI: Magnetic resonance imaging, cPET: Positron emission tomography, dCE: Contrast-enhanced, e TCGA –TCIA: The 
Cancer Genome Atlas-The Cancer Imaging Archive, f CEIPs: computer-extracted image phenotypes, gER: estrogen receptor, hPR: progesterone receptor, 
iCNVs: copy number variations, jNSCLC: Non-small cell lung cancer, kSRE: Short-Run Emphasis, lLRE: Long-Run Emphasis, mRLNU: Run Length Non-
Uniformity,n LGLZE: Low Gray-Level Zone Emphasis, oHGLZE: High Gray-level Zone Emphasis, pSUV :standardized uptake value, qEGFR: epidermal growth 
factor receptor, rGSEA: Gene Set Enrichment analysis, sAUC: area under the curve, tVEGF: vascular endothelial growth factor  
 










































































Feature selection and 
statistical learning 











24 semantic radiological 
traits ( location, size, shape, 
margin, density, internal 
features, external features, 
associated findings) used to 
create a linear classification 
model 
Accuracy/AUROCe , 
Hold-out cross-validation,  
Bootstrap,  Youden J index 
 
Radiological image traits are 
useful in predicting malignancy 











104(T) + 92(V); 
benign:  
208(T) + 196 (V) 
219 three-dimensional 
features (size, shape, 





Convolutional Neural Networks, 
Random Forest classifier 
Radiomics features are 
effective in the prediction of 
malignant vs. benign lung 
nodules with accuracies of 












440 radiomic features (voxel 
intensity distribution, shape, 
texture matrices) 
Correlation-based feature 
elimination and univariate feature 
selection. 24 feature selection 
and 3 classification methods 
tested 
Radiomics features predict 
NSCLC histology (highest 


















features learned from a deep 
convolutional neural network 
learning architecture 
Deep convolutional neural 
network; binary decision tree 
classifier 
Method used outperforms the 
state-of-the art approach for 
lung nodule benign vs. 
malignant classification 
(accuracy 77%, sensitivity 










T: 1100 nodules 
 




Learned classifiers from the 
neural network algorithm 
Multi-scale Convolutional 
Neural Networks 
The convolutional neural 
network method used showed 











T: 54 nodules 
 
V: 86 nodules 
Computer-aided nodule 
assessment and risk yield 
(CANARY) : representative 
exemplars of the spectrum of 
solid and ground glass 
components of nodules 
Affinity propagation 
(unsupervised clustering),  
Multinomial logistic regression, 
nonparametric Spearman 
correlation 
CANARY can noninvasively 
characterize pulmonary 
nodules of the adeno-
carcinoma spectrum, with the 
exemplar distribution within 
each nodule correlating well 
with the proportion of histologic 















63 2D low-level image 
features from four 
categories: shape, texture, 
intensity, size 
Multiple-label belief decision 
trees,  
5-fold cross validation 
Multiple-label classification 
algorithms are an appropriate 
method of representing the 
diagnoses of radiologists on 







T: 147 first and second order 
texture statistics from 
intensity distribution(mean, 
SDh, skewness,kurtosis); 




Support Vector Machine 
Texture features predicts 
benign vs malignant prostate 
lesions and Gleason score 
prediction  of malignant 
tumors, with  a better accuracy 
(93%) than using diffusion MRI 
alone  
* aCT: Computed tomography scan, bMRI: Magnetic resonance imaging, dCE: Contrast-enhanced, eAUROC: area under the receiver operating characteristic,  
fNLST: National Lung Cancer Screening Trial, gLIDC-IDRI: Lung Image Database Consortium, hSD: standard deviation, iAUC: area under the curve 
 

















































































T: 31, 21, 422 
 
V: 225, 136, 95, 89 
 












Significant associations were 
found between imaging 
features and tumor  stage  and 
overall survival, with the 
radiomics signature having a 









T: Lung - 422 
HN - 136 
 
V: Lung 2 - 225 
HN2 - 95 
440 radiomics features 
(tumor intensity, shape, 
texture, wavelet) 
 
Consensus clustering Significant agreement in the 
clusters between training and 
validation sets was seen. 
Features were associated with 
stage (lung AUCi = 0.61, H&N 
AUCi = 0.77), HPV status (H&N 
AUCi = 0.58) and prognosis 












635 radiomics features 
(intensity, shape, texture , 
Laplacian of Gaussian and 




Imaging features aid in the 
identification of patients at risk of 
developing distant metastases 









T:: (cohort 1 = 61; 
cohort 2 = 47) 
 










Increasing tumor entropy and 
lower convexity are associated 
with overall survival, even after 










4,842 total  
17 first-order 
features ,9 volume and 
shape features, 162 
texture features 
Supervised principal 
component analysis,  
Cox proportional 




of recurrent glioblastoma 
permits the prediction of 
treatment outcome to 
antiangiogenic therapy through 





















Radiomics nomogram predicts 
lymph node metastases 

















the radiomics score 
Texture features can be utilized 
in preoperative staging of 









2015 [88]  
 
 
V: 542 radiomics signature 
(energy, Compactness, 




Results show the applicability 
as a prognostic index of a 
radiomics signature which was 
trained in lung and H&N and 
cancer validated well in an 
external cohort of OPSCC (CIh 
= 0.63) 
Breast Cancer 















analysis with logistic 
regression 
CEIPs predict the recurrence 
risk as assessed by Oncotype 
Dx, PAM50 or Mammaprint 
(AUCsi  from 0.55 to 0.88) 
 
* aCT: Computed tomography scan, bMRI: Magnetic resonance imaging, dCE: Contrast-enhanced , eTCGA –TCIA: The Cancer Genome Atlas-The Cancer 
Imaging Archive, fNSCLC: Non-small cell lung cancer, gHNSCC: Head and Neck Squamous cell carcinoma, hCI: Concordance Index, iAUC: area under the 
curve, jLASSO: least absolute shrinkage and selection operator, kPFS: progression-free survival, lOS: overall survival, mCEIPs: computer-extracted image 
phenotypes 
 









































































Feature selection and 
statistical learning 









V: 31 (Rider 
Test-retest)  
183 initial features,  
11 independent features 
used (volume, Gabor 
Energy, Sigmoid 
Function, Shape Index, 
Boundary Radius, 
GLCMg, Laws Energy) 
Spearman rank statistic,  
AUC, intraclass correlation 
coefficient 
Radiomics features predict EGFRi 
mutation status and associated 
response to Gefitinib in baseline 
(AUCj = 0.67) and in change in pre- 
and post treatment (AUCi = 0.74–




Y Liu,  
2016 [91] 
T: 385  Semantic radiologic 





assessed by 3 
radiologists 




CT features of lung adeno- 
carcinomas can be an image 
biomarker for EGFRi mutation 
status, with the use of clinical 
variables combined with CT 
features (AUROCm = 0.778) being 
superior to use of clinical variables 





2015 [95]  
T: 47 First-order and high-order 
primary tumor texture 
features 
Cox and logistic regression 
analyses 
Reduced quantitative heterogeneity 
features (percentage change in 
entropy) in PET scans are 
associated with time to disease 








T: 22 mean density, first-order 
texture, en rgy, entropy, 
correlation, inverse 
difference moment, 
inertia, cluster shade, and 
cluster prominence 
Independent samples t-test 
with unequal variances, 
Kolmogorov-Smirnov test, 
Wilcoxon signed rank test 
linear Bayes normal 
classifier, Spearman rank 
correlation coefficients 
First and second-order texture 
features can predict eventual 
cancer recurrence based on CT 
images acquired within 5 months of 










T: 65 36 spatial habitat 
diversity (regions with 
distinctly different 
intensity characteristics) 
features based on pixel 
abundances w/in  ROIs 
Overall coefficient of 
variation; symbolic 
regression method  
Features had association with 
overall survival (AUC=0.74) and 
EGFR+ (AUC=0.85) status and 
could be a useful prognostic tool for 






T: 69 20 texture, 3 kinetic, BI-
RADS and biologic 
parameters 
Logistic regression model, 
k-means clustering 




Radiomics features predicts 
response to neoadjuvant 
chemotherapy (accuracy = 68%), 







T: 100 Texture features based 
on co-occurrence 
matrices (Haralick 
features, cluster shade, 
cluster prominence) 
Mann–Whitney, t-tests 




Certain texture parameters are 
significantly associated with 
treatment response (best-
performing features p= 0.039-0.048) 
and tumor histology (best-






T: 48 103 imaging features  
(texture, shape, 
histogram) 
Mean-value based and 
voxelized analysis 
techniques; three-layer 
perceptron artificial neural 
network, feed-forward 
-back-propagation learning 
Features reflect response to 
neoadjuvant therapy (AUC = 0.71 to 
0.79 in voxelized analysis) and 
could influence treatment plans 






T: 27 First-order primary tumor 
texture features 
(coefficient of variation, 
skewness, kurtosis)  
ROC analysis, Youden 
index 
Texture features reflect response to 
neoadjuvant chemoradiotherapy 
and prognostic capability for 
disease progression (AUC = .89 for 
the coefficient of variation feature) 
 




































































T: 39 First order statistics 
(Entropy and uniformity), 
TEXRAD 
Cox regression model Heterogeneity biomarkers are 
associated with treatment response 
and time to progression (AUC = 
0.71); with prediction rates better 
than standard response criteria 










scans + mid 
treatment 
scan 
66 radiomic features  
(raw T2wk signal, post-
processed T2w, 30 post-
processed T2w textures, 
raw ADCl map, 30 ADC 
textures, SUV, 2 PET 
textures) 
 
Cox proportional hazards 
model  
 
SUV and both T2w and ADC 
texture features appear to be able 
to capture subvisual TKI treatment-
related changes in RCCs, with the 
highest-ranked radiomics feature 
yielding a normalized percentage 
change of 63% within the RCC 
region 
* aCT: Computed tomography scan, bMRI: Magnetic resonance imaging, cPET: Positron emission tomography, dCE: Contrast-enhanced, e TCGA –TCIA: The 
Cancer Genome Atlas-The Cancer Imaging Archive, fNSCLC: Non-small cell lung cancer, gGLCM: gray level co-concurrence matrix, hSABR: Stereotactic 
ablative body radiotherapy iEGFR: epidermal growth factor receptor, j AUC: area under the curve,  kT2 Weighted MRI,  lADC: apparent diffusion coefficient, 
mAUROC:  Area under the receiver operating characteristic 
  

































































Figure 3: Comparison of key biomarker and radiomics studies  
Figure 3  
223x241mm (300 x 300 DPI)  
 
 






























































Table 5. Issues and solutions for radiomics studies 
STEP PITFALL SOLUTION 




Differences in acquisition parameters 
 
Need for standardized protocols adapted to each modality (CT, 
PET, MRI); and comprehensive description of the parameters 
being used.  
Exclusion of images with outlier acquisition parameters. 
Contrast enhancement protocols vary across machines 
and across patients (sarcopenia, adipose level, heart 
rate, etc). 
Standardized control ROIs such as muscle  
Image Segmentation 
  
Intra/inter-observer variability Semi-automatic segmentation with human 
correction/improvement 




Large range of voxel intensities and image noise Filtering procedure aiming to preserve the signal and reduce the 
unwanted noise 
Different discretization methods producing different 
results 
Using fixed bin sizes (absolute discretization) 
Volume dependence Testing for correlation between radiomics variables and volume 
Statistical Learning 
  
Large number of features, small population (p>>n) 
resulting into a high probability of false positives results 
and overfitting, the “curse of dimensionality” 
Bonferroni, Benjamini-Hochberg corrections 
Cross-validation 
Dimensionality reduction through supervised and unsupervised 
(PCAa, ICAb, ISOMAP,LLEc) techniques 
Feature selection and classification uncertainties, 
susceptibility to human error  
Advanced machine learning approaches such as neural 
networks 
General Reproducibility is limited Publications should include access to raw data, segmented 
ROIs, methods used for feature extraction 
A repository should be initiated containing imaging data, 
radiomics features, extraction software, methods, formulae and 
statistical learning methods 
aPrinicipal Component Analysis, bIndependent Component Analyses, cLocally Linear Embedding 
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